The Association Between Anticholinergic Medication Burden and Health Related Outcomes in the ‘Oldest Old’: A Systematic Review of the Literature

Drugs and Aging

Volumn 32, Issue 10, 2015, Pages 835-848

  Cardwell, Karen ^a   Hughes, Carmel M ^a   Ryan, Cristín ^a,b  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT;

AGED; COGNITION; COGNITIVE DEFECT; DRUG BURDEN INDEX; FALLING; GERIATRIC PATIENT; HUMAN; LONGITUDINAL STUDY; MORTALITY; OUTCOME ASSESSMENT; PHYSICAL DISEASE; PRIORITY JOURNAL; RATING SCALE; REVIEW; SYSTEMATIC REVIEW; VERY ELDERLY; CHEMICALLY INDUCED; FACTUAL DATABASE; FEMALE; MALE; RISK; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ACCIDENTAL FALLS; AGED, 80 AND OVER; CHOLINERGIC ANTAGONISTS; COGNITION DISORDERS; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; RISK; TREATMENT OUTCOME;

EID: 84944448966     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-015-0310-9     Document Type: Review

References (61)

1. United Nations Department of Economic and Social Affairs Population Division. World population ageing 2013. http://www.un.org/en/development/desa/population/publications/pdf. Accessed 26 Mar 2015.
2. Hayman KJ, Kerse N, Dyall L, et al. Life and living in advanced age: a cohort study in New Zealand-Te Puāwaitanga o Nga Tapuwae Kia Ora Tonu. LiLACS NZ: study protocol. BMC Geriatr. 2012;12:33.
3. Collerton J, Barrass K, Bond J, et al. The Newcastle 85+ Study: biological, clinical and psychosocial factors associated with healthy ageing: study protocol. BMC Geriatr. 2007;7:14.
4. Cronin H, O’Regan C, Finucane C, et al. Health and aging: development of the Irish Longitudinal Study on Ageing Health Assessment. J Am Geriatr Soc. 2013;61:S269–78.
5. Meinow B, Parker MG, Thorslund M. Complex health problems and mortality among the oldest old in Sweden: decreased risk for men between 1992 and 2002. Eur J Ageing. 2010;7:81–90.
6. Linjakumpu T, Hartikainen S, Klaukka T, et al. Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol. 2002;55:809–17.
7. Guthrie B, Payne K, Alderson P, et al. Adapting clinical guidelines to take account of multimorbidity. BMJ. 2012;345:e6341.
8. Hughes LD, McMurdo MET, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. Age Ageing. 2013;42:62–9.
9. Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet. 2007;370:173–84.
10. Bradley MC, Fahey T, Cahir C, et al. Potentially inappropriate prescribing and cost outcomes for older people: a cross-sectional study using the Northern Ireland Enhanced Prescribing Database. Eur J Clin Pharmacol. 2012;68:1425–33.
11. Cahir C, Fahey T, Teeling M, et al. Potentially inappropriate prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 2010;69:543–52.
12. Gallagher PF, Barry PJ, Ryan C, et al. Inappropriate prescribing in an acutely ill population of elderly patients as determined by Beers’ Criteria. Age Ageing. 2008;37:96–101.
13. Dalleur O, Spinewine A, Henrard S, et al. Inappropriate prescribing and related hospital admissions in frail older persons according to the STOPP and START Criteria. Drugs Aging. 2012;29:829–37.
14. Lau DT, Kasper JD, Potter DEB, et al. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med. 2005;165:68–74.
15. Sumukadas D, McMurdo MET, Mangoni AA, et al. Temporal trends in anticholinergic medication prescription in older people: repeated cross-sectional analysis of population prescribing data. Age Ageing. 2014;43:515–21.
16. Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2003;57:6–14.
17. Han L, Agostini JV, Allore HG. Cumulative anticholinergic exposure is associated with poor memory and executive function in older men. J Am Geriatr Soc. 2008;56:2203–10.
18. Kersten H, Wyller TB. Anticholinergic drug burden in older people’s brain—how well is it measured? Basic Clin Pharmacol Toxicol. 2014;114:151–9.
19. Ehrt U, Broich K, Larsen JP, et al. Use of drugs with anticholinergic effect and impact on cognition in Parkinson’s disease: a cohort study. J Neurol Neurosurg Psychiatry. 2010;81:160–5.
20. Tune L, Coyle JT. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch Gen Psychiatry. 1980;37:293–7.
21. Durán CE, Azermai M, Vander Stichele RH. Systematic review of anticholinergic risk scales in older adults. Eur J Clin Pharmacol. 2013;69:1485–96.
22. Carnahan RM, Lund BC, Perry PJ, et al. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46:1481–6.
23. Rudolph JL, Salow MJ, Angelini MC, et al. The Anticholinergic Risk Scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168:508–13.
24. Lertxundi U, Domingo-Echaburu S, Hernandez R, et al. Expert-based drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics. 2013;13:17–24.
25. Hilmer SN, Mager DE, Simonsick EM, et al. A drug burden index to define the functional burden of medications in older people. Arch Intern Med. 2007;167:781–7.
26. Gnjidic D, Le Couteur DG, Abernethy DR, et al. Drug Burden Index and Beers Criteria: impact on functional outcomes in older people living in self-care retirement villages. J Clin Pharmacol. 2012;52:258–65.
27. Kouladjian L, Gnjidic D, Chen TF, et al. Drug Burden Index in older adults: theoretical and practical issues. Clin Inter Aging. 2014;9:1503–15.
28. Fox C, Smith T, Maidment I, et al. Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43:604–15.
29. Salahudeen MS, Duffull SB, Nishtala PS. Impact of anticholinergic discontinuation on cognitive outcomes in older people: a systematic review. Drugs Aging. 2014;31:185–92.
30. Salahudeen MS, Duffull SB, Nishtala PS. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31.
31. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–9.
32. Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.
33. Ottawa Hospital Research Institute. The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2014. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 26 Mar 2015.
34. Kaufmann CP, Tremp R, Hersberger KE, et al. Inappropriate prescribing: a systematic overview of published assessment tools. Eur J Clin Pharmacol. 2014;70:1–11.
35. Taipale HT, Hartikainen S, Bell JS. A comparison of four methods to quantify the cumulative effect of taking multiple drugs with sedative properties. Am J Geriatr Pharmacother. 2010;8:460–71.
36. Best O, Gnjidic D, Hilmer SN, et al. Investigating polypharmacy and drug burden index in hospitalised older people. Intern Med J. 2013;43:912–8.
37. Wilson NM, Hilmer SN, March LM, et al. Associations between Drug Burden Index and falls in older people in residential aged care. J Am Geriatr Soc. 2011;59:875–80.
38. Wilson NM, Hilmer SN, March LM, et al. Associations between Drug Burden Index and mortality in older people in residential aged care facilities. Drugs Aging. 2012;29:157–65.
39. Kalisch Ellett LM, Pratt NL, Ramsay EN, et al. Multiple anticholinergic medication use and risk of hospital admission for confusion or dementia. J Am Geriatr Soc. 2014;62:1916–22.
40. Bostock CV, Soiza RL, Mangoni AA. Associations between different measures of anticholinergic drug exposure and Barthel Index in older hospitalized patients. Ther Adv Drug Saf. 2013;4:235–45.
41. Lowry E, Woodman RJ, Soiza RL, et al. Associations between the Anticholinergic Risk Scale score and physical function: potential implications for adverse outcomes in older hospitalized patients. J Am Med Dir Assoc. 2011;12:565–72.
42. Dauphinot V, Faure R, Omrani S, et al. Exposure to anticholinergic and sedative drugs, risk of falls, and mortality: an elderly inpatient, multicenter cohort. J Clin Psychopharmacol. 2014;34:565–70.
43. Han L, McCusker J, Cole M, et al. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med. 2001;161:1099–103.
44. Kersten H, Molden E, Tolo IK, et al. Cognitive effects of reducing anticholinergic drug burden in a frail elderly population: a randomized controlled trial. J Gerontol Biol Sci Med Sci. 2013;68:271–8.
45. Koyama A, Steinman M, Ensrud K, et al. Long-term cognitive and functional effects of potentially inappropriate medications in older women. J Gerontol Biol Sci Med Sci. 2014;69:423–9.
46. Lampela P, Lavikainen P, Garcia-Horsman JA, et al. Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study. Drugs Aging. 2013;30:321–30.
47. Lönnroos E, Gnjidic D, Hilmer SN, et al. Drug Burden Index and hospitalization among community-dwelling older people. Drugs Aging. 2012;29:395–404.
48. Yeh Y-C, Liu C-L, Peng L-N, et al. Potential benefits of reducing medication-related anticholinergic burden for demented older adults: a prospective cohort study. Geriatr Gerontol Int. 2013;13:694–700.
49. Lowry E, Woodman RJ, Soiza RL, et al. Clinical and demographic factors associated with antimuscarinic medication use in older hospitalized patients. Hosp Pract. 2011;39:30–6.
50. Summers WK. A clinical method of estimating risk of drug induced delirium. Life Sci. 1978;22:1511–6.
51. Boustani M, Campbell N, Munger S, et al. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4:311–20.
52. Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc. 2008;56:1333–41.
53. Nissen D. Mosby’s drug consult. St Louis: Mosby Inc.; 2004.
54. Duplay D. Physicians’ desk reference: PDR. 58th ed. Montvale: Thomson PDR; 2004.
55. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 2015. http://www.whocc.no/filearchive/publications/2015_guidelines.pdf. Accessed 05 Aug 2015.
56. Casarosa P, Kiechle T, Sieger P, et al. The constitutive activity of the human muscarinic M3 receptor unmasks differences in the pharmacology of anticholinergics. J Pharmacol Exp Ther. 2010;333:201–9.
57. Campbell N, Boustani M, Limbil T, et al. The cognitive impact of anticholinergics: a clinical review. Clin Interv Aging. 2009;4:225–33.
58. Lampela P, Hartikainen S, Sulkava R, et al. Adverse drug effects in elderly people—a disparity between clinical examination and adverse effects self-reported by the patient. Eur J Clin Pharmacol. 2007;63:509–15.
59. Sambrook PN, Cameron ID, Chen JS, et al. Does increased sunlight exposure work as a strategy to improve vitamin D status in the elderly: a cluster randomised controlled trial. Osteoporos Int. 2012;23:615–24.
60. Culp KR, Wakefield B, Dyck MJ, et al. Bioelectrical impedance analysis and other hydration parameters as risk factors for delirium in rural nursing home residents. J Gerontol Biol Sci Med Sci. 2004;59:813–7.
61. Simonsick EM, Newman AB, Nevitt MC, et al. Measuring higher level physical function in well-functioning older adults: expanding familiar approaches in the Health ABC Study. J Gerontol Biol Sci Med Sci. 2001;56:M644–9.